Zoetis Inc. $ZTS Stock: Carnegie Lake Advisors LLC Cuts Stake

Carnegie Lake Advisors LLC lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 93.4% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 490 shares of the company’s stock after selling 6,934 shares during the quarter. Carnegie Lake Advisors LLC’s holdings in Zoetis were worth $34,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Zoetis in the second quarter worth about $25,000. Dunhill Financial LLC boosted its position in shares of Zoetis by 519.3% in the second quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock valued at $25,000 after acquiring an additional 296 shares during the period. Cassaday & Co Wealth Management LLC bought a new position in shares of Zoetis in the first quarter valued at approximately $28,000. Wellington Grp LLC boosted its position in shares of Zoetis by 6,675.0% in the first quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after acquiring an additional 267 shares during the period. Finally, Provenance Wealth Advisors LLC grew its stake in Zoetis by 1,866.7% during the third quarter. Provenance Wealth Advisors LLC now owns 531 shares of the company’s stock valued at $37,000 after acquiring an additional 504 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

NYSE:ZTS opened at $79.50 on Monday. The business’s 50-day moving average price is $75.68 and its two-hundred day moving average price is $92.60. Zoetis Inc. has a twelve month low of $68.77 and a twelve month high of $132.49. The stock has a market cap of $32.85 billion, a P/E ratio of 13.52, a PEG ratio of 1.15 and a beta of 0.67. The company has a quick ratio of 1.40, a current ratio of 2.35 and a debt-to-equity ratio of 2.51.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, November 5th. The company reported $1.75 EPS for the quarter, topping the consensus estimate of $1.51 by $0.24. Zoetis had a return on equity of 85.90% and a net margin of 26.15%. The company had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same quarter in the previous year, the firm earned $1.70 earnings per share. Zoetis’s revenue was down 1.3% on a year-over-year basis. As a group, equities analysts predict that Zoetis Inc. will post 6.25 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be given a dividend of $0.53 per share. The ex-dividend date is Friday, October 30th. This represents a $2.12 annualized dividend and a yield of 2.7%. Zoetis’s payout ratio is presently 36.05%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ZTS shares. UBS Group upped their target price on shares of Zoetis from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Tuesday, October 27th. Cantor Fitzgerald set a $94.00 target price on shares of Zoetis in a research note on Tuesday, August 25th. Citigroup cut their price target on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. Morgan Stanley reduced their price target on shares of Zoetis from $85.00 to $82.00 and set an “overweight” rating for the company in a research report on Thursday, October 29th. Finally, Leerink Partners decreased their price target on shares of Zoetis from $95.00 to $80.00 and set a “market perform” rating on the stock in a report on Monday, July 13th. Eight investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $101.25.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Adjusted EPS of $1.75 topped the $1.51 consensus, while revenue of $2.39 billion exceeded expectations of $2.30 billion. Zoetis also raised its full-year 2026 profit outlook. Zoetis Lifts Annual Outlook While Braces For Cautious Pet Economy
• Positive Sentiment: Livestock revenue grew 7% to $797 million, helping offset softness in companion-animal products. Jefferies also raised its price target to $85 from $83. Zoetis: 3 Key Takeaways for Long-Term Investors
• Negative Sentiment: Investors appear focused on ongoing pressure in the pet-health business: owners are cutting back on veterinary visits, and Zoetis is taking a cautious view of 2027. Competitive pressures and margin headwinds also weigh on the outlook. Zoetis plans cautiously for 2027 as pet owners cut back on vet visits, shares fall ZTS Q3 2026 deep dive: Competitive pressures and margin headwinds weigh on outlook
• Negative Sentiment: Despite beating estimates, quarterly revenue declined 1.3% year over year, reinforcing concerns that strength in livestock may not fully offset weaker companion-animal demand. Zoetis reports third-quarter results

Zoetis Profile

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish.

The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.

Zoetis originated as Pfizer’s animal health business and became an independent public company in 2013.